ICH E2D(R1) 上市后安全数据管理指南进入第 4 阶段,EMA 已发布并将于 2026 年 3 月 18 日适用
ICH E2D(R1) Guideline on Safety Data Management reaches Step 4
ICH E2D(R1)《上市后安全数据:个例安全性报告管理与报告的定义和标准》已到达 ICH 进程第 4 阶段,并进入第 5 阶段实施阶段。EMA 已发布该指南,将于 2026 年 3 月 18 日起在欧盟法律框架内适用。修订版更新了上市后药品安全信息管理报告的定义、标准与监管指导,并新增针对采用原始数据收集的非干预性研究及二手数据使用的非干预性研究的安全数据管理指导。
材料说明 ICH E2D(R1) 已进入第 4 阶段并在欧盟自 2026 年 3 月 18 日起适用,可帮助读者定位上市后安全数据管理与报告的定义和标准更新。
The ICH E2D(R1) Guideline on “Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports” has reached Step 4 of the ICH Process and has now entered the implementation phase at Step 5 of the ICH Process. Background & UpdatesThe E2D guideline provides guidance on definitions and standards for post-approval individual case safety reporting, as well as good case management practices. Where applicable, the guideline notes where regional and local requirements may vary and, as such, marketing authorisation holders (MAHs) should refer to the relevant regional or local regulatory authority’s requirements. Since its original publication new sources of post-approval safety information have emerged or are more frequently used (e.g. digital platforms, social media, mobile health technologies, market research programs, patient support programs, non-interventional studies, literature), which vary in characteristics and contributions to the quality of the safety data received. The revised Guideline ICH E2D(R1) thus provides updates on the definitions, standards, and regulatory guidance for the management and reporting of post-approval drug safety information. It aims to support appropriate safety surveillance of medicinal products based on the current practices and needs. New guidance is also included focusing on the management of safety data from non-interventional studies with primary data collection, as well as from non-interventional studies with secondary use of data. The European Medicines Agency (EMA) has now published the guideline, which will be applied within the European legal framework starting 18 March 2026. Further information can be found on the ICH E2D(R1) page, including the Guideline and a Step 4 Introductory Training Presentation available for download, and on the EMA website.
来源:ECA GMP News · gmp-compliance.org